medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2013, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2013; 30 (2)

Enteral Iboprufen for Ductus Arteriosus Closure. Neonatology Service at the Hospital Infantil del Estado de Sonora

Rojas-Villalvazo JM, Ramírez-Rodríguez CA, Sosa-Cruz EF, Corella-Valencia J

Language: Spanish
References: 15
Page: 76-79
PDF size: 498.77 Kb.


ABSTRACT

Introduction: Patent ductusarteriosus (PDA) is the most common cardiocirculatory defects in preterm infants . It has an incidence of 80% in less than 1,000 g and / or 28 weeks gestation. A hemodynamically significant patent ductusarteriosus (PDA-HS) is symptomatic and evidenced by echocardiogram and always requires treatment. Indomethacin is the drug of first choice for PDA closure in hospitals without intravenous indomethacin has recommended the use of intravenous ibuprofen with similar results have been reported using ibuprofen enterally with a close range DAP than 80% and no increase in adverse events. In Mexico we do not have both presentations of intravenous medications which justifies the use of enteral ibuprofen with caution and recommend appropriate guidelines to raise the profile on safety and efficacy of this treatment modality.
Methodology: We performed a literature search of the past 10 years on medical and surgical treatment for PDA closure, and focused specifically toward closure enteral ibuprofen, based mainly on Cochrane Library, established meta-analysis and consensus.
Results: We developed a guide (algorithm) management attached to the results of the literature review.


REFERENCES

  1. 1.- Golombek SG, Sola A, Baquero H et al. Primer consenso clínico de SIBEN: Enfoque diagnóstico y terapeutico del ductus arterioso permeable en recién nacidos pretermino. AnPediatr (Barc), 2006; 69(5); 454-81.

  2. 2.- Polin and Fox; Phisiology Neonatal; Mechanisms Regulating the Closure of the DuctusArteriosus; 2010: 821-5.

  3. 3.- Piña PP; Tesis: Morbimortalidad del RN con peso < 1,500g en la UCIN del Hospital Infantil de México Federico Gómez en el periodo del 1 de Agosto de 2001 al 31 de Julio de 2004.

  4. 4.- NayaranMeera S, Clyman Roland I. Pharmacologic clousure of patent ductusarteriousus in the neonate. NeoReviews, 2003; 3(8); e215-21.

  5. 5.- Yeh TF, Luken JA, Thalji A. Intravenous indomethacin therapy in premature infants with persistent ductusarteriousus. A double-blind controlled study. J Pediatr; 1981; 98: 137-45.

  6. 6.- Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductusarteriousus in preterm infants. Cochrane Library; 2004.

  7. 7.- Kazou Itabashi Ohno. Indomethacin responsiveness of patent ductusarteriousus and renal abnormalities in preterm infants treatment with indomethacin. J Pediatr; 2003; 143; 203-7.

  8. 8.- Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductusarteriousus in preterm infants. Cochrane Library, 12 Septiembre 2002.

  9. 9.- Eli Heyman; Iris Morag; David Batash; RimonaKeidar; Saul Baram; MatitihauBerkovitch; Closure of Patent DuctusArteriosus with oral ibuprofen in premature newborn: A Pilot Study. Pediatrics, 2003; 112(5); e354-8.

  10. 10.- Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductusarteriousus in preterm and/or low birth weight infants. Cochrane Library. 22 Septiembre 2005.

  11. 11.- Ohlsson A, Walia R, Shah S. Ibuprofen for the prevention of patent ductusarteriousus in preterm and/or low birth weight infants. Cochrane Library. 19 Septiembre 2007. 12.- Akýsü M, Özyürek AR, Dorak C, et al. Enteral ibuprofen versus indomethacin in the treatment of PDA in preterm newborn infants [in Turkish]. ÇocukSaglýgýveHastalýklarýDergisi. 2001; 44: 56–60.

  12. 13.- Heyman E, Morag I, Batash D, et al. Closure of patent ductusarteriosus with oral ibuprofen suspension in premature newborns: A pilot study. Pediatrics. 2003; 112: e354.

  13. 14.- Cherif A, Khrouf N, Jabnoun S, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductusarteriosus. Pediatrics. 2008; 122: e1256–e1261.

  14. 15.- Salama H, Alsisi A, Al-Rifai H, et al. A randomized controlled trial on the use of oral ibuprofen to close patent ductusarteriosus in premature infants. J Neonatal Perinatal Med. 2008;1:153–158.

  15. 16.- Bell EF, Acarregui MJ. Restricted versus




2020     |     www.medigraphic.com